ABC-101

About Abcely

Abcely is an early-stage biotech developing the world's first platform for orally active secretory IgA (sIgA) immunotherapies, targeting high-value markets in mucosal oncology and inflammatory diseases. Its proprietary technology aims to rapidly generate optimized drug candidates with superior mucosal targeting and penetration compared to conventional IgG antibodies. The company operates a dual business model of building its own pipeline and pursuing out-licensing opportunities, with three disclosed preclinical programs in colorectal cancer, endometriosis, and inflammatory bowel disease.

Therapeutic Areas